Acute Coronary Syndrome (ACS) represents a significant cause of morbidity and mortality worldwide. The management of ACS is complex and requires a multifaceted approach. This article aims to provide an overview of the effective strategies for ACS management.
Risk stratification is crucial for determining the appropriate treatment strategy for ACS. The use of validated risk scores such as the GRACE or TIMI risk scores can aid in identifying high-risk patients who may benefit from early invasive strategies.
Pharmacologic therapy forms the cornerstone of ACS management. Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is recommended for all patients with ACS. Additionally, anticoagulants, beta-blockers, angiotensin-converting enzyme inhibitors (ACEI), and statins have demonstrated efficacy in reducing adverse cardiovascular events.
Early invasive strategies, including percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), have been shown to improve outcomes in high-risk patients. The selection between PCI and CABG should be individualized based on patient characteristics and coronary anatomy.
Secondary prevention measures, including lifestyle modifications and cardiac rehabilitation, are essential components of ACS management. These measures can reduce the risk of recurrent events and improve quality of life.
In conclusion, ACS management requires a comprehensive approach involving risk stratification, pharmacologic therapy, invasive strategies, and secondary prevention measures. Ongoing research and technological advancements will continue to refine these strategies, with the ultimate goal of improving patient outcomes.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation